David A. Sinclair A.O., Ph.D.

David A. Sinclair A.O., Ph.D. has a long and distinguished career in the field of biology and aging research. In 1999, they began their career as a Professor at Harvard University. In 2005, they co-founded the Paul F. Glenn Center for Biology of Aging Research, where they served as Co-Director. From 2010 to 2013, they co-founded and served as Co-Founder and Scientific Advisor for CohBar, Inc. In 2013, they co-founded Metrobiotech International, where they served as Co-founder, Board Member, Scientific Advisor, and Investor. In 2015, they co-founded Liberty BioSecurity, LLC, where they served as Co-Founder, Chief Scientific Advisor, and Investor. In 2016, they co-founded Arc Bio and served as Co-Founder, Board Member, Advisor, and Investor. David A. also served as a Member of the Board, Advisor, and Investor for EdenRoc Sciences. In 2017, they joined Life Biosciences as a Board Member, Investor, and Advisor. In 2020, they co-founded Immetas Therapeutics, where they serve as Co-founder and Board Member. In 2022, they co-founded Tally Health, where they serve as Co-Founder.

David A. Sinclair A.O., Ph.D. began their educational career at the University of New South Wales (UNSW) where they obtained a B.S. and Ph.D. between 1987 and 1995 in the fields of Genetics, Molecular Biology, Biochemistry, and Marine Biology. Following their studies at UNSW, they completed postdoctoral training at the Massachusetts Institute of Technology (MIT) between 1995 and 1999 in the field of Genetics.